DUBLIN--(BUSINESS WIRE)--The "IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application - Global Forecast to 2031" report has been added to ...
GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic ...
REDDING, Calif., Oct. 24, 2024 /PRNewswire/ -- According to a new market research report, 'IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering (Assay Development, ...
Register for our upcoming webinar “Accelerate your IVD assay development with the unique support of the Dynabeads team” and learn how Dynabeads technology and commercial partnership can help ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, ...
The CFX Opus 96 Dx System and the CFX Opus 384 Dx Real-Time PCR Systems Offer Accurate and Precise Quantification to Improve IVD Assay Development and Diagnostic Testing. Bio-Rad Laboratories, Inc.
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ ...
The growth of IVD assay development market is driven by the rising prevalence of chronic diseases & the increasing geriatric population, the high burden of infectious diseases, the growing focus on ...
The new partnership combines QIAGEN’s QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX’s expertise in multiplex assay development. The aim is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback